Lei Zhang1, Yan-Jun Su1, Jia-Yue Chen2, Zhi-Chao Liao3, Zhi-Qin Luo4, Shu-Min Xie5, Jing Zhang2, Yun-Shou Lin2, Hui Guo2, Wei-Lin Sun2, Begüm Pekbay6, Adam R Miller7, Le Luo8, Yu-Hua Rui5, Mo-Han Li5, Chang-Li Wang9. 1. Department of Thoracic Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Center, Tianjin, 300060, People's Republic of China. 2. Tianjin Medical University, Tianjin, People's Republic of China. 3. Department of Bone and Softissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China. 4. Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China. 5. Xiangya School of Medicine, Central South University, Changsha, People's Republic of China. 6. Erasmus University Rotterdam, Rotterdam, Netherlands. 7. Indiana University School of Medicine, Indianapolis, IN, USA. 8. Department of Radiation Oncology, Tumor Hospital Xiangya School of Medicine of Central South University, Changsha, People's Republic of China. 9. Department of Thoracic Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Center, Tianjin, 300060, People's Republic of China. 13189368@qq.com.
Abstract
PURPOSE: Our aim is to test the validity, reliability, and acceptability of the Chinese version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Bone Metastases 22 (EORTC QLQ-BM22) module to assess health-related quality of life (HRQOL) in patients with bone metastases in China. METHODS: Patients with histological confirmation of malignancy and bone metastases from Tianjin Cancer Institution and Hospital from June 2013 to April 2014 were enrolled in this study. All patients self-administered the EORTC QLQ-BM22 and the EORTC QLQ-C30. The Karnofsky Performance Scale (KPS) was performed to evaluate scores. The reliability and validity tests of the questionnaires were based on Cronbach's α coefficients, Pearson correlation test, and Wilcoxon rank sum nonparametric test. RESULTS: Internal consistency reliabilities of all the four scales were acceptable. Scales measuring similar HRQOL aspects were found to correlate with one another between EORTC QLQ-BM22 and EORTC QLQ-C30, but differences still existed. Significant differences were demonstrated in the scores of all four subscales of the QLQ-BM22 between the two KPS subgroups (KPS ≤ 80; KPS > 80). Meanwhile, the compliance for item completion of the QLQ-BM22 was satisfactory. CONCLUSIONS: The Chinese version of EORTC QLQ-BM22 is a reliable and valid instrument, which is appropriate for measuring the HRQOL of patients with bone metastases in China.
PURPOSE: Our aim is to test the validity, reliability, and acceptability of the Chinese version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Bone Metastases 22 (EORTC QLQ-BM22) module to assess health-related quality of life (HRQOL) in patients with bone metastases in China. METHODS:Patients with histological confirmation of malignancy and bone metastases from Tianjin Cancer Institution and Hospital from June 2013 to April 2014 were enrolled in this study. All patients self-administered the EORTC QLQ-BM22 and the EORTC QLQ-C30. The Karnofsky Performance Scale (KPS) was performed to evaluate scores. The reliability and validity tests of the questionnaires were based on Cronbach's α coefficients, Pearson correlation test, and Wilcoxon rank sum nonparametric test. RESULTS: Internal consistency reliabilities of all the four scales were acceptable. Scales measuring similar HRQOL aspects were found to correlate with one another between EORTC QLQ-BM22 and EORTC QLQ-C30, but differences still existed. Significant differences were demonstrated in the scores of all four subscales of the QLQ-BM22 between the two KPS subgroups (KPS ≤ 80; KPS > 80). Meanwhile, the compliance for item completion of the QLQ-BM22 was satisfactory. CONCLUSIONS: The Chinese version of EORTC QLQ-BM22 is a reliable and valid instrument, which is appropriate for measuring the HRQOL of patients with bone metastases in China.
Entities:
Keywords:
Bone metastases; EORTC QLQ-BM22; Health-related quality of life; Validation
Authors: Edward Chow; Amanda Hird; Galina Velikova; Colin Johnson; Linda Dewolf; Andrea Bezjak; Jackson Wu; Jesmin Shafiq; Orhan Sezer; Dimitrios Kardamakis; Yvette van der Linden; Brigette Ma; Monica Castro; Palmira Foro Arnalot; Sam Ahmedzai; Mark Clemons; Peter Hoskin; Albert Yee; Michael Brundage; Andrew Bottomley Journal: Eur J Cancer Date: 2008-12-25 Impact factor: 9.162
Authors: Marko Popovic; Janet Nguyen; Emily Chen; Julia Di Giovanni; Liang Zeng; Edward Chow Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2012-04 Impact factor: 2.217
Authors: Mir S Yekaninejad; Ahmad Ahmadzadeh; Seyed H Mosavi; Mohsen Saffari; Amir H Pakpour; Fatemeh Tolooei; Edward Chow; Andrew Bottomley Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2013-12-13 Impact factor: 2.217
Authors: Mirosława Püsküllüoğlu; Krzysztof A Tomaszewski; Andrew Bottomley; Lori Holden; Iwona M Tomaszewska; Roman Głowacki; Krzysztof Bereza; Edward B Golec; Edward Chow; Krzysztof Krzemieniecki Journal: Qual Life Res Date: 2013-08-03 Impact factor: 4.147